

Antitumor and antioxidant activity of some metal complex compounds

Stefka Ivanova¹, Stefan Balkanski², Petar Atanasov³, Maria Chaneva³, Danka Obreshkova⁴, Valentin Dimitrov⁵, Krasimira Kazalukova⁶, Lily Peikova⁷, Ognian Markov⁴

¹ Department of Chemistry and Biochemistry, Faculty of Pharmacy, Medical University Pleven, Pleven, Bulgaria

² Bulgarian Pharmaceutical Union, Sofia, Bulgaria

³ Clinic of Internal Diseases UMHATEM “N. I. Pirogov”, Sofia, Bulgaria

⁴ Hospital Pharmacy, UMHATEM “N. I. Pirogov”, Sofia, Bulgaria

⁵ Administrative department, UMHATEM “N. I. Pirogov”, Sofia, Bulgaria

⁶ Department of Physical and Rehabilitation Medicine, UMHATEM „N.I. Pirogov”, Sofia, Bulgaria

⁷ Department of Pharmaceutical Chemistry, Medical University of Sofia, Sofia, Bulgaria

Corresponding author: Stefan Balkanski (st.balkanski@gmail.com)

Received 2 May 2023 ♦ Accepted 29 May 2023 ♦ Published 7 June 2023

Citation: Ivanova S, Balkanski S, Atanasov P, Chaneva M, Obreshkova D, Dimitrov V, Kazalukova K, Peikova L, Markov O (2023) Antitumor and antioxidant activity of some metal complex compounds. *Pharmacia* 70(2): 375–382. <https://doi.org/10.3897/pharmacia.70.e105845>

Abstract

In the last few years, interest in platinum drugs has increased. Successful treatment depends to a large extent on complex therapy and early diagnosis, which determines the great importance of knowledge of risk groups, clinical symptoms, and targeted use of diagnostic methods with biomarkers, biopsy and diagnostic imaging for early detection of the malignant process. Today, the mono-target strategy is being replaced by a poly-target therapy strategy, which achieves greater clinical efficacy in tumors with defined biomarkers. Key developments include elucidation of the mechanisms of tumor resistance to these drugs, the introduction of some new platinum-based agents and clinical combination studies using platinum drugs with resistance modulators or new drug-targeted drugs. Improved delivery of platinum drugs to tumors has been studied in early clinical trials using liposomal or copolymer-based products. Other investigated as anticancer agents are ruthenium and iron complexes. Ln(III) complexes have been shown to exert antioxidant activity.

Keywords

Platinum and non-platinum metal-based organic complexes, lanthanides, ligands, with potential anticancer activity, antioxidant activity

I. Metal complexes stability

Metals and their related ions are an integral part of living organisms. Biogenic metals play a crucial role in the diverse processes of life, e.g., gas transport, enzymatic catalytic reactions, chemical signalling, etc (Roat-Malone 2007).

Responsible for the antineoplastic properties of drugs containing some metal complexes is thought to be the metal ion (Kostova 2005; Fricker 2006), and many of these

ions have attractive coordination chemistry (Bünzli 2005). For example, the high coordination number of lanthanide complexes and their substitution lability are the major factors in the coordination of biomolecules.

The “hard” and “soft” metal ion concentration (HSAI), also known as Pearson’s acid-base concept, is widely used in chemistry to explain the stability of compounds, reaction mechanisms and pathways. In general, “hard” metal ions have a small atomic radius, a high effective nuclear

charge, and a low polarizability, whereas “soft” ions have the opposite characteristics (Pearson 1963, 2005; Ho 2002). Calculations of the interaction of the metal ions Mg(II), Ca(II), Li(I), and Na(I) with thymine (5-methyluracil) have been performed (Sagarik and Rode 1983). The results show that there are two suitable sites for electrophilic attack, O(2) and O(4), with relative binding energies in the following order Mg(II)>Ca(II)>Li(I)>Na(I). Although for metal ions the metal-oxygen bond length is the same 36 at O(2) and O(4), the bond energy at metal-O(4) is greater than that at metal-O(2). The influence of methylated isomers of uracil on their noncovalent interactions with alkali metals has been studied. Both theoretical and experimental studies have been carried out by mass spectral fragmentation. Five different forms of methylated uracil, xMeU = 1-methyluracil, 3-methyluracil, 6-methyluracil, 1,3-dimethyluracil, and 5,6-dimethyluracil, were used (Yang and Rodgers 2005). Comparison of lithium complexes of adenine, uracils, and thymine revealed that the most stable structure for adenine was obtained upon bidentate coupling of Li/L⁺ to the N7 atom of the imidazole ring and the NH2 group of the pyrimidine ring. For uracil and thymine, the most stable Li/Li⁺ bond is at the O4 atom (Krasnokutski et al. 2010). Complexes of neutral uracil and thymine with coordination at O(4) have also been reported (Goodgame and Johns 1977). Complexes of the general formula (MX₂L_n).xH₂O have been obtained, where X = Cl⁻, Br⁻, ClO⁻, NO⁻; L = uracil or thymine; n = 1, 2; x = 0, 1, 2, 3, 4; M = Mn(II), Co(II), Ni(II), Cu(II), Zn(II), Cd(II). All complexes are insoluble in nonpolar solvents and decompose in polar solvents. Many of the complexes are hygroscopic and their degree of hydration varies (Sarkar and Ghosh 1983).

Mixed ligand complexes in which uracil is the primary ligand and adenine is the secondary ligand are also described. It is concluded that the 1:1 metal-uracil and 1:1:1 metal-uracyladenine bonding is mediated by the N(3) atom, with uracil in its dihydroxy form. The greater stability of the 1:1:1 complex compared to 1:1 is presumably caused by the interactions between uracil and adenine. A most probable structure is also presented. The synthesis and characterization of mixed complexes of uracil and glycine with Cu(II), Ni(II), Co(II) and Zn(II) are reported. The results show that glycine is bidentate in each case, while uracil appears as a bidentate 40 ligand at the Cu(II) complex, binding via one carbonyl oxygen and one nitrogen atom, and is monodentate in the other cases, binding only via the nitrogen atom (Gupta and Srivastava 1985).

II. Platinum complexes

Platinum compounds such as Cisplatin, Oxaliplatin, (Fig. 1), and Carboplatin (Fig. 2), well-known metal-based antitumor chemotherapy drugs, have serious side effects (Gao et al. 2017a, 2017b).

This has led to an increased demand for metal complexes with low toxicity and improved therapeutic characteristics




Figure 1. Chemical structures of cisplatin and oxaliplatin.




Figure 2. Chemical structures of carboplatin.

as antineoplastic agents (Gaber et al. 2017; Kumaravel et al. 2018; Y.-X. Liu et al. 2018; Martínez et al. 2018; Qi et al. 2018; Tang et al. 2018; Weng et al. 2018; Yi et al. 2018).

The discovery of the mechanism of action and the main structure-activity dependencies of platinum complexes and the observed serious side effects of Cisplatin, Oxaliplatin, and Carboplatin (Gao et al. 2017a, 2017b), create opportunities for rational synthesis of new Cisplatin analogues as potential antitumor drugs with reduced resistance, low toxicity and/or a wider spectrum of antitumor activity, and improved therapeutic characteristics as antineoplastic agents (Gaber et al. 2017; Kumaravel et al. 2018; Y.-X. Liu et al. 2018; Martínez et al. 2018; Qi et al. 2018; Tang et al. 2018; Weng et al. 2018; Yi et al. 2018).

In Table 1 are presented some Pt II complexes with anticancer and antioxidant activity.

Table 1. Pt II complexes with anticancer and antioxidant activity.

Ligand
1) (4-{2-[(2-hydroxy-benzylidene)-amino]-ethyl}-benzene-1,2-diol) [278] (Kareem et al. 2021)
2) (1 <i>H</i> -1,2,4-triazole-3-ylimino)methyl)naphthalene-2-ol [285] (Gaber et al. 2015)
3) 1-(benzo[<i>d</i>]thiazol-2-yl)-3-phenylthiourea (Jambi 2017)
4) macroacyclic ligands [287] (Keypour et al. 2020)

In the field of targeted synthesis of antitumor complexes has been working hard for 40 years. Initial research focused on obtaining complexes with a structure similar to Cisplatin, and later on the search for new “non-classical” antitumor complexes. Approaches to the synthesis of such compounds include: development of new structures based on knowledge of the biochemical mechanism of action of Cisplatin. For overcoming the drug resistance and reduction of toxicity of Cisplatin derivatives is the application of nanocarriers (polymers and liposomes), which provide

improved targeted delivery, increased intracellular penetration, selective accumulation in tumor tissue, and enhanced therapeutic efficacy. An important approach for overcoming the drug resistance and for reduction of toxicity is the combination therapy of liposomal encapsulated Cisplatin and Oxaliplatin with other anticancer agents, which provide improved targeted delivery, improved intracellular penetration, selective accumulation in tumor tissue, and enhanced therapeutic efficacy.

One of the strategies to reduce the overall toxicity and resistance is the use of “prodrugs” that can be activated locally by internal stimuli - physiological changes in the environment (pH, redox potential); by enzyme-catalyzed chemical transformation or by external stimuli such as light.

III. Non-platinum metal complexes

Various strategies for the synthesis of antitumor agents have been developed, such as selection of a suitable ligand system, ensuring effective accumulation in the antitumor tissue (Da Silva and Williams 2001). Replacement of platinum with other metals of the platinum group – ruthenium and palladium or metals with similar properties, such as gold (Halliwell 2006; Momekov et al. 2013). Changing the degree of oxidation of the metal ion with for the purpose of kinetic and thermodynamic control over the binding of the metal complex to DNA bases. Different investigated metal organic complexes have been reported to be promising agents for biomedical applications (Loginova et al. 2019) in medicine and pharmacy (Habala and Valentová 2020). The possibilities of medicinal applications in the therapy of coordination complexes are increased (Mohammed and Tripathi 2020). Due to the specific mechanisms of action (Boros et al. 2020) and different pharmacological activities (Selvaganapathy and Raman 2016), metallopharmaceuticals provide new trend for scientific research (Chylewska et al. 2017), and for perspectives in the discovery and development (Anthony et al. 2020) of drug design Singh et al. 1991).

Metal complexes of silver (Ag), arsenic (As - metalloid), gold (Au), boron (B - metalloid), bismuth (Bi), cobalt (Co), chromium (Cr), copper (Cu), iron (Fe), magnesium (Mg), manganese (Mn), molybdenum (Mo), nickel (Ni), antimony (Sb - metalloid), zinc (Zn), cerium (Ce), europium (Eu), gallium (Ga), gadolinium (Gd), iridium (Ir), lanthanum (La), neodymium (Nd), osmium (Os), palladium (Pd), rhenium (Re), rhodium (Rh), ruthenium (Ru), samarium (Sm), selenium (Se - metalloid), titanium (Ti), vanadium (V), and tungsten (W), are potential therapeutic agents for medical applications (Turel 2015), due to possess potential antiproliferative activity (Bruijninx and Sadler 2008; P. Zhang and Sadler 2017).

Some complexes of metals have been approved as drugs with potential effects on some cancer. Orally active Auranofin was approved from FDA in 1985 as an anti-rheumatic drug, which inhibits cathepsins. Combinations with Auranofin have been investigated towards different types of cancer: non-small cell lung, small cell lung and

ovarian cancer, and over chronic lymphocytic leukemia (Bruijninx and Sadler 2008).

In the US in 2003 was approved the proteasome inhibitor Bortezomib for treating a multiple myeloma (Selvaganapathy and Raman 2016)

The more common used ligands are derivatives of pyridine (Marcon et al. 2002; Auzias et al. 2008; Ali et al. 2013; J. Chen et al. 2015; Poynton et al. 2017; Mital and Ziora 2018), pyrazine (Tan et al. 2014), imidazole (Medvetz et al. 2008), benzimidazole (S. Liu et al. 2013; Song et al. 2014), oxadiazole (Maftai et al. 2015), 1,10-phenanthroline (Luís et al. 2014), quinoline (H. R. Zhang et al. 2016), thiazole (Tan et al. 2014), and thiosemicarbazone (Stanojkovic et al. 2010; Manikandan et al. 2014). Very often in structures of organic complexes of Ag(I) (Maftai et al. 2015), Au(I) (Maftai et al. 2015; Mora et al. 2019), Ni(II) (Ray et al. 2009), and Ir(I) (F. Chen et al. 2018) are included N-heterocyclic carbenes, with substituents as 1,2,4-oxadiazole (Maftai et al. 2015; Mora et al. 2019), imidazole (Medvetz et al. 2008), and Caffeine (Bertrand et al. 2014).

The important trend in cancer treatment is the investigation of new non-platinum metal complexes, which possess similar antiproliferative effect, but at lower concentrations than Cisplatin, or higher anticancer effect and best selectivity than Cisplatin. In the investigations for the development of non-platinum compounds with a promising therapeutic potential in current therapy in cancer, Ru complexes are among the most investigated, and advanced organic agents.

1. Ruthenium complexes

Ru complexes are among the most investigated, and advanced organic agents, and are a promising candidate for the increased efficiency of anticancer activity, and for excellent selectivity over healthy cells/tissues.

The superior anticancer activity of Ru complexes than Cisplatin are a result of their increased selectivity toward cancer cells. In 2008 in phase I/II study NAMI-A in combination with Gemcitabine was applied in patients with non-small cell lung cancer.

It has been demonstrated that NAMI-A exhibit selective activity against lung metastases of solid metastasizing tumors with mild toxicity over Cisplatin as a result from its reduced reactivity against DNA in intact cells.

The Ru(II) complexes, which have been entered in clinical trials are NAMI-A with imidazole and dimethylsulfoxide ligands, trans-tetrachlorobis-(1H-indazole)ruthenate (III)] (KP 1019) and KP1339.

It has been reported that NAMI-A possesses antimetastatic activities in secondary tumors, and KP1019 is active against primary tumors. Ru complexes show similar or better efficacy compared to platinum agents.

2. Ferrocene complexes

The antiproliferative potential show Ferrocene-podophyllotoxin (Beaupérin et al. 2017). The compound [3-ferrocenyl-6-methoxybenzo[*b*]thiophen-2-yl][4-(piperazin-1-yl)

methyl-phenyl] methanone is even more potent than the reference compound Cisplatin (Ferreira et al. 2009).

3. Lanthanides complexes

3.1. Medical applications of lanthanides

Lanthanides have some well-established medical applications - as MRI contrast agents, bactericides, and wound treatment. Their potential antiviral, antineoplastic and anti-inflammatory properties are being extensively investigated. The role of lanthanum-containing complexes as diagnostic tools in medicine and biology as well as their potential therapeutic applications has also been discussed in scientific literature. Gadolinium (III) ion with its available seven unpaired electrons is one of the most preferred for NMR medical application. Two other ions, Dysprosium

(III) and Holmium (III), have much larger magnetic moments than Gadolinium, but the symmetric S-state of Gadolinium results in a slower and more favorable NMR electron relaxation rate that is more suitable for the excitation of water molecules, as noted by Roat-Malone (Roat-Malone 2007). There is significant interest in radiolabeled biomolecules as target-specific radiopharmaceuticals in the diagnosis and treatment of cancer. DOTA (1,4,7,10-tetraazacyclododecanetetraacetic acid) and its analogues are used as bifunctional chelators to produce a variety of radiolabeled biomolecules.

3.2. Oxidative stress

Free radicals contain unpaired electrons, making them highly reactive and non-selective in their chemical interactions. Thus, they damage various biomolecules (intracellular, extracellular and membrane). This leads to toxin formation, tissue damage and development of pathological processes. For this reason, elevated levels of some substances harmful to the body lead to toxic effects, can alter the redox state of cells, cause DNA damage leading to cell death (apoptosis/necrosis). The formation of free radicals as a result of normal physiological processes in living organisms is compensated by a number of antioxidant defense mechanisms. A disturbed balance between radical formation and elimination, in which free radical accumulation predominates, is defined as oxidative stress. Free radicals react with all biomolecules, including antioxidants. This can lead to depletion of antioxidant enzyme activity, release of metal ions from ion-binding proteins, and depletion of radical scavengers. All these factors lead to the inability of antioxidant defenses to control oxidative stress. It can also be compromised by any disturbances of metal ion homeostasis (Halliwell 2007).

3.3. Antioxidant and antineoplastic activity of lanthanides

The potential antioxidant and antineoplastic activity of lanthanides are being extensively investigated. Lanthanide based coordination complexes as anticancer agents are classified based on different ligands such as acridine, benzothio-

azole, coumarin, 5-fluorouracil, phenanthroline, plumbagin, porphyrins, quercetin, quinolone, schiff bases, transferrin, and miscellaneous ligands (Chundawat et al. 2021).

Lanthanides cannot be administered as simple salts or metal ions in clinical practice because of their toxic effect. In studies on mice treated with several different lanthanide chlorides, significant oxidative damage to the lungs was observed due to a simultaneous weakening of antioxidant defense mechanisms and an increase in reactive parts (RP) production. Long-term exposure to LaCl₃ in mice is known to result in significant impairment of memory and spatial orientation. Intracellular Ca²⁺ in hippocampal cells was increased, whereas Ca²⁺-dependent ATPase activity was suppressed. There was a dose-dependent increase in malondialdehyde (MDA) and attenuation of SOD, CAT and GPx in the cerebral cortex and hippocampus (Zheng et al. 2000).

The described property of some elements to induce oxidative stress makes their simple salts and coordination complexes significant targets in the development of antitumor drugs. Of particular interest are complexes of these metals with organic ligands that exhibit antioxidant properties. Lanthanides can be administered as a stable complex. The basic idea of this approach is the transport of the metal ions to the target tissue, with their release from the complex taking place in the tumor. There, the metal ion can stimulate the formation of free radicals, destroying the tumor by apoptosis. Ligands play an important role in coordinating the properties of the respective complexes (Krinochkin et al. 2015) and they are particularly important for biological, biochemical, and medical applications (Bünzli and Eliseeva 2013).

Various Ln(III) complexes have been described in the literature to have significant biological activities, e.g. DNA binding and antioxidant activity (B. dui Wang et al. 2007; Q. Wang et al. 2009; Xu et al. 2009), and the exhibited cytotoxic activity of lanthanide complexes is usually attributed to lanthanide-DNA interactions, inhibition of calcium transport in mitochondria (Reed and Bygrave 1974), and apoptosis of the endoplasmic reticulum (Kwong et al. 2013). Inhibition of thioredoxin reductase and targeting of the glutathione-independent lipoate reduction pathway by gadolinium (III) texaphrin (MGd, Xcytrin) is the other important mechanism by which cancer cell replication is subsequently inhibited in DNA, restored, and oxidative stress induced (Citta et al. 2012). Tumorigenesis, for example, could be induced by iron overload and iron-mediated oxidative stress. Lanthanides competitively inhibit iron uptake, inhibit iron-mediated formation by interacting with hydroperoxides, participate in magnetic interactions with free radicals, thus affecting signal transduction. For this reason, lanthanide compounds are being investigated for antitumor activity and could potentially affect a wide range of iron-dependent pathologies (Cho et al. 2013).

It has been shown that La (III) complex containing 2,2'-bipyridine ligand exert *in vitro* cytotoxicity towards MCF-7 (breast cancer) and A-549 cell lines (Aramesh-Boroujeni et al. 2021). The complexes of La(III) with usnic acid (2,6-diacetyl-7,9-dihydroxy-8,9-dimethyl-1,3(2*H*,9*bH*)-dibenzofurandione) were more

toxigenic against tumor cells MCF-7 (breast cancer) than in normal breast tissue cells (MCF-10A), demonstrating selectivity. (Nunes et al. 2020).

3.4. Lanthanum(III) complexes

3.4.1. Dinuclear lanthanum(III) complexes

It has been reported that dinuclear lanthanide complex with ligand *N*'-(2-hydroxybenzylidene) nicotinohydrazide exhibits specific cytotoxicity to A549 cancer cells and less toxicity than Cisplatin for normal human cells HUVEC (Song et al. 2020). A binuclear La(III) complex $\{[La_2(HA)_4(H_2O)_4(C_2H_5OH)_2Cl_2]Cl_4\}$ (C1) with 2-aminobenzoic acid exerts cytotoxicity against human breast (MDA-MB-231), prostate (PC-3) and bladder (T-24) cancer cells (Zidan et al. 2022).

3.4.2. Dimeric lanthanum(III) complexes

It has been described that dimeric lanthanum(III) complex with 1,10-phenanthroline shows in vitro cytotoxicity against A-549 cell (Niroomand et al. 2023).

3.4.3. Lanthanum mixed ligand complexes

It has been investigated that primary Schiff base of lanthanum (III) benzimidazole complex with ligand 2-(1H-benzimidazol-2-ylmethyliminomethyl) phenol in vitro exerts cytotoxicity on the HCT116 cell line superior to that observed with the HEPG2 cell line (El-Sayed and Alhakimi 2022).

3.4.4. La-based metal organic frameworks

It has been described that a La-based metal organic frameworks can be used for anticancer delivery of 3,4-dihydroxycinnamic acid shows cytotoxicity against the human breast cancer cell line MDA-MB-468 (Safinejad et al. 2022).

3.4.5. Nano-structure La (III) complexes

Lanthanide nanoparticles (Nanoceria) are not only small molecules but also exhibit *in vitro* cytotoxicity to various human cancer cells, such as pancreatic, hepatocellular,

and squamous-cell carcinoma (Momekov et al. 2013; Wason and Zhao 2013). This cytotoxicity may result from induction of oxidative stress, activation of mitogen-activated protein kinase, and mimics of superoxide dismutase, glutathione peroxidase, and catalase activity (Cheng et al. 2013; Wason and Zhao 2013). It has been demonstrated that nano structure metal complexes of La (III) with two different nitrogen donor tridentate ligands: *N*-(2-Aminoethyl)-1,3-propanediamine and 1-(2-Aminoethyl)piperazine possess antitumor activity. (Hassan and Mohamed 2020).

Conclusion

A future trend is the widespread use of platinum-containing regimens with a new generation of molecularly targeted therapies in combination with carboplatin and paclitaxel in patients with lung cancer. The introduction of different leaving groups and / or carrier ligands leads to significant changes both in the antitumor activity and spectrum of action and in the toxicological profile of platinum analogues.

This expands the possibilities for search and development of new platinum complexes as antitumor drugs in; development of platinum complexes with high oral bioavailability; increasing the crossing of the blood-brain barrier and developing platinum-directed platinum cytostatic.

Lanthanide nanoparticles exert *in vitro* cytotoxicity against pancreatic, hepatocellular, and squamous-cell carcinoma.

Other trend is the synthesis of mixed ligand complexes with Cu(II), Ni(II), Co(II) and Zn(II).

The synthesis and study of complex compounds has a targeted nature related to the discovery of the diverse potential biological possibilities, a logical consequence of the diverse properties of the starting ligand and complexing agents with a view to a future rational approach in the selection of metals and biologically active ligands.

References

- Ali KA, Abd-Elzاهر MM, Mahmoud K (2013) Synthesis and Anticancer Properties of Silver(I) Complexes Containing 2,6-Bis(substituted) pyridine Derivatives. *International Journal of Medicinal Chemistry* 2013: 256836. <https://doi.org/10.1155/2013/256836>
- Anthony EJ, Bolitho EM, Bridgewater HE, Carter OWL, Donnelly JM, Imberti C, Lant EC, Lermyte F, Needham RJ, Palau M, Sadler PJ, Shi H, Wang FX, Zhang WY, Zhang Z (2020) Metalloodrugs are unique: opportunities and challenges of discovery and development. *Chemical Science* 11(48): 12888–12917. <https://doi.org/10.1039/D0SC04082G>
- Aramesh-Boroujeni Z, Aramesh N, Jahani S, Khorasani-Motlagh M, Kerman K, Noroozifar M (2021) Experimental and computational interaction studies of terbium (III) and lanthanide (III) complexes containing 2, 2'-bipyridine with bovine serum albumin and their *in vitro* anticancer and antimicrobial activities. *Journal of Biomolecular Structure and Dynamics* 39(14): 5105–5116. <https://doi.org/10.1080/07391102.2020.1792988>
- Beaupérin M, Polat D, Roudesly F, Top S, Vessières A, Oble J, Jaouen G, Poli G (2017) Approach to ferrocenyl-podophyllotoxin analogs and their evaluation as anti-tumor agents. *Journal of Organometallic Chemistry* 839: 83–90. <https://doi.org/10.1016/j.jorganchem.2017.02.005>
- Bertrand B, Stefan L, Pirrotta M, Monchaud D, Bodio E, Richard P, Le Gendre P, Warmerdam E, De Jager MH, Groothuis GMM, Picquet M, Casini A (2014) Caffeine-based gold(I) N-heterocyclic carbenes as possible anticancer agents: Synthesis and biological properties. *Inorganic Chemistry* 53(4): 2296–2303. <https://doi.org/10.1021/ic403011h>
- Boros E, Dyson PJ, Gasser G (2020) Classification of Metal-Based Drugs according to Their Mechanisms of Action. *Chem* 6(1): 41–60. <https://doi.org/10.1016/j.chempr.2019.10.013>

- Bruijninx PC, Sadler PJ (2008) New trends for metal complexes with anticancer activity. *Current Opinion in Chemical Biology* 12(2): 197–206. <https://doi.org/10.1016/j.cbpa.2007.11.013>
- Bünzli J-CG (2005) Benefiting from the unique properties of lanthanide ions. *Accounts of Chemical Research* 39(1): 53–61. <https://doi.org/10.1021/ar0400894>
- Bünzli J-CG, Eliseeva SV (2013) Intriguing aspects of lanthanide luminescence. *Chemical Science* 4(5): 1939–1949. <https://doi.org/10.1039/c3sc22126a>
- Chen F, Moat J, McFeely D, Clarkson G, Hands-Portman IJ, Furner-Pardoe JP, Harrison F, Dowson CG, Sadler PJ (2018) Biguanide iridium(III) complexes with potent antimicrobial activity. *Journal of Medicinal Chemistry* 61(16): 7330–7344. <https://doi.org/10.1021/acs.jmedchem.8b00906>
- Chen J, Luo Z, Zhao Z, Xie L, Zheng W, Chen T (2015) Cellular localization of iron(II) polypyridyl complexes determines their anticancer action mechanisms. *Biomaterials* 71: 168–177. <https://doi.org/10.1016/j.biomaterials.2015.08.031>
- Cheng G, Guo W, Han L, Chen E, Kong L, Wang L, Ai W, Song N, Li H, Chen H (2013) Cerium oxide nanoparticles induce cytotoxicity in human hepatoma SMMC-7721 cells via oxidative stress and the activation of MAPK signaling pathways. *Toxicology in Vitro* 27(3): 1082–1088. <https://doi.org/10.1016/j.tiv.2013.02.005>
- Cho M, Eze OP, Xu R (2013) A brief review of the controversial role of iron in colorectal carcinogenesis. *Journal of Clinical and Experimental Pathology* 3(1): 137. <https://doi.org/10.4172/2161-0681.1000137>
- Chundawat NS, Jadoun S, Zarrintaj P, Chauhan NPS (2021) Lanthanide complexes as anticancer agents: A review. *Polyhedron* 207: 115387. <https://doi.org/10.1016/j.poly.2021.115387>
- Chylewska A, Biedulska M, Sumczynski P, Makowski M (2017) Metallopharmaceuticals in therapy - a new horizon for scientific research. *Current Medicinal Chemistry* 25(15): 1729–1791. <https://doi.org/10.2174/0929867325666171206102501>
- Citta A, Folda A, Scutari G, Cesaro L, Bindoli A, Rigobello MP (2012) Inhibition of thioredoxin reductase by lanthanum chloride. *Journal of Inorganic Biochemistry* 117: 18–24. <https://doi.org/10.1016/j.jinorgbio.2012.08.014>
- Da Silva FJJR, Williams RJP (2001) *The Biological Chemistry of the Elements: The Inorganic Chemistry of Life*. Oxford University Press, 2nd edn., 600 pp.
- El-Sayed SS, Alhakimi AN (2022) Synthesis, characterization of Lanthanum mixed ligand complexes based on benzimidazole derivative and the effect of the added ligand on the antimicrobial, and anticancer activities. *Journal of Qassim University for Science* 15: 35–53.
- Ferreira AP, Ferreira Da Silva JL, Duarte MT, Fátima Minas Da Piedade M, Paula Robalo M, Harjivan SG, Marzano C, Gandin V, Matilde Marques M (2009) Synthesis and characterization of new organometallic benzo[b]thiophene derivatives with potential antitumor properties. *Organometallics* 28(18): 5412–5423. <https://doi.org/10.1021/om9003835>
- Fricker SP (2006) The therapeutic application of lanthanides. *Chemical Society Reviews* 35(6): 524–533. <https://doi.org/10.1039/b509608c>
- Gaber M, El-Ghamry HA, Fathalla SK (2015) Ni (II), Pd (II) and Pt (II) complexes of (1*H*-1,2,4-triazole-3-ylimino)methyl]naphthalene-2-ol. Structural, spectroscopic, biological, cytotoxicity, antioxidant and DNA binding. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 139(1): 396–404. <https://doi.org/10.1016/j.saa.2014.12.057>
- Gaber M, Khedr AM, Elsharkawy M (2017) Characterization and thermal studies of nano-synthesized Mn(II), Co(II), Ni(II) and Cu(II) complexes with adipohydrazone ligand as new promising antimicrobial and antitumor agents. *Applied Organometallic Chemistry* 31(12): e3885. <https://doi.org/10.1002/aoc.3885>
- Gao E, Ding Y, Sun N, Zhang S, Qiu X, Zhan Y, Zhu M (2017a) Synthesis, characterization DNA interaction, apoptosis and molecular docking of Cu(II) and Mn(II) complexes with endo-norbornene-cis-5,6-dicarboxylic acid. *Applied Organometallic Chemistry* 31(3): e3575. <https://doi.org/10.1002/aoc.3575>
- Gao E, Qi Z, Qu Y, Ding Y, Zhan Y, Sun N, Zhang S, Qiu X, Zhu M (2017b) Two novel dinuclear ellipsoid Ni(II) and Co(II) complexes bridged by 4,5-bis(pyrazol-1-yl)phthalic acid: Synthesis, structural characterization and biological evaluation. *European Journal of Medicinal Chemistry* 136: 235–245. <https://doi.org/10.1016/j.ejmech.2017.05.005>
- Goodgame M, Johns KW (1977) Metal complexes of uracil and thymine. *Journal of the Chemical Society Dalton Transactions* 17: 1680–1683. <https://doi.org/10.1039/dt9770001680>
- Gupta M, Srivastava MN (1985) Synthesis and characterization of mixed ligand complexes of copper(II), nickel(II), cobalt(II) and zinc(II) with glycine and uracil or 2-thiouracil. *Polyhedron* 4(3): 475–479. [https://doi.org/10.1016/S0277-5387\(00\)87013-8](https://doi.org/10.1016/S0277-5387(00)87013-8)
- Habala L, Valentová J (2020) Metal complexes in medicine and pharmacy - the past and the present III. *Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti* 69(3): 121–129. <https://europemc.org/article/med/32972155>
- Halliwell B (2006) Reactive Species and Antioxidants. Redox Biology Is a Fundamental Theme of Aerobic Life. *Plant Physiology* 141(2): 312–322. <https://doi.org/10.1104/pp.106.077073>
- Halliwell B (2007) Cellular responses to oxidative stress: adaptation, damage, repair, senescence and death. *Free Radicals in Biology and Medicine* 187–267. <https://cir.nii.ac.jp/crid/1571135651242856832>
- Hassan SS, Mohamed EF (2020) Antimicrobial, antioxidant and antitumor activities of Nano-Structure Eu (III) and La (III) complexes with nitrogen donor tridentate ligands. *Applied Organometallic Chemistry* 34(2): e5258. <https://doi.org/10.1002/aoc.5258>
- Ho TL (2002) Hard soft acids bases (HSAB) principle and organic chemistry. *Chemical Reviews* 75(1): 1–20. <https://doi.org/10.1021/cr60293a001>
- Jambi MS (2017) Quantum, characterization and spectroscopic studies on Cu (II), Pd (II) and Pt (II) complexes of 1-(benzo[d]thiazol-2-yl)-3-phenylthiourea and its biological application as antimicrobial and antioxidant. *Journal of Molecular Structure* 1143(C): 217–228. <https://doi.org/10.1016/j.molstruc.2017.04.065>
- Kareem MJ, Al-Hamdani AAS, Jirjees VY, Khan ME, Allaf AW, Al-Zoubi W (2021) Preparation, spectroscopic study of schiff base derived from dopamine and metal Ni (II), Pd (II), and Pt (IV) complexes, and activity determination as antioxidants. *Journal of Physical Organic Chemistry* 34(3): 1–15. [e4156] <https://doi.org/10.1002/poc.4156>
- Keypour H, Ansari N, Mahmoudabadi M, Karamian R, Farida SHM, Moghadam ME, Gable RW (2020) Mn (III), Zn (II) and Pt (II) macrocyclic complexes: Synthesis X-ray structures, anticancer and antioxidant activities. *Inorganica Chimica Acta* 509(11): 119705. <https://doi.org/10.1016/j.ica.2020.119705>
- Kostova I (2005) Lanthanides as Anticancer Agents. *Current Medicinal Chemistry-Anti-Cancer Agents* 5(6): 591–602. <https://doi.org/10.2174/156801105774574694>

- Krasnokutski SA, Lee JS, Yang DS (2010) High-resolution electron spectroscopy and structures of lithium-nucleobase (adenine, uracil, and thymine) complexes. *The Journal of Chemical Physics* 132(4): 044304. <https://doi.org/10.1063/1.3299278>
- Krinochkin AP, Kopchuk DS, Kozhevnikov DN (2015) Luminescent neutral lanthanide complexes of 5-aryl-2,2'-bipyridine-6-carboxylic acids, synthesis and properties. *Polyhedron* 102: 556–561. <https://doi.org/10.1016/j.poly.2015.09.055>
- Kumaravel G, Utthra PP, Raman N (2018) DNA fastening and scission actions of Cu(II), Co(II), Ni(II) and Zn(II) complexes: synthesis, spectral characterization and cytotoxic study. *Applied Organometallic Chemistry* 32(2): e4010. <https://doi.org/10.1002/aoc.4010>
- Kwong W-L, Sun RW-Y, Lok C-N, Siu F-M, Wong S-Y, Low K-H, Che C-M (2013) An ytterbium(III) porphyrin induces endoplasmic reticulum stress and apoptosis in cancer cells: cytotoxicity and transcriptomics studies. *Chemical Science* 4(2): 747–754. <https://doi.org/10.1039/C2SC21541A>
- Liu S, Cao W, Yu L, Zheng W, Li L, Fan C, Chen T (2013) Zinc(II) complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers that trigger DNA damage-mediated p53 phosphorylation in cancer cells. *Dalton Transactions* 42(16): 5932–5940. <https://doi.org/10.1039/c3dt33077j>
- Liu Y-X, Mo H-W, Lv Z-Y, Shen F, Zhang C-L, Qi Y-Y, Mao Z-W, Le X-Y (2018) DNA binding, crystal structure, molecular docking studies and anticancer activity evaluation of a copper(II) complex. *Transition Metal Chemistry* 43(3): 259–271. <https://doi.org/10.1007/s11243-018-0211-y>
- Loginova NV, Harbatsevich HI, Osipovich NP, Ksendzova GA, Kovalchuk TV, Polozov GI (2019) Metal Complexes as Promising Agents for Biomedical Applications. *Current Medicinal Chemistry* 27(31): 5213–5249. <https://doi.org/10.2174/0929867326666190417143533>
- Luis DV, Silva J, Tomaz AI, De Almeida RFM, Larginho M, Baptista PV, Martins LMDRS, Silva TFS, Borralho PM, Rodrigues CMP, Rodrigues AS, Pombeiro AJL, Fernandes AR (2014) Insights into the mechanisms underlying the antiproliferative potential of a Co(II) coordination compound bearing 1,10-phenanthroline-5,6-dione: DNA and protein interaction studies. *Journal of Biological Inorganic Chemistry* 19: 787–803. <https://doi.org/10.1007/s00775-014-1110-0>
- Maftei CV, Fodor E, Jones PG, Freytag M, Franz MH, Kelter G, Fiebig HH, Tamm M, Neda I (2015) N-heterocyclic carbenes (NHC) with 1,2,4-oxadiazole-substituents related to natural products: Synthesis, structure and potential antitumor activity of some corresponding gold(I) and silver(I) complexes. *European Journal of Medicinal Chemistry* 101: 431–441. <https://doi.org/10.1016/j.ej-mech.2015.06.053>
- Manikandan R, Viswanathamurthi P, Velmurugan K, Nandhakumar R, Hashimoto T, Endo A (2014) Synthesis, characterization and crystal structure of cobalt(III) complexes containing 2-acetylpyridine thiosemicarbazones: DNA/protein interaction, radical scavenging and cytotoxic activities. *Journal of Photochemistry and Photobiology B: Biology* 130: 205–216. <https://doi.org/10.1016/j.jphotobiol.2013.11.008>
- Marcon G, Carotti S, Coronello M, Messori L, Mini E, Orioli P, Mazzei T, Cinelli MA, Minghetti G (2002) Gold(III) complexes with bipyridyl ligands: Solution chemistry, cytotoxicity, and DNA binding properties. *Journal of Medicinal Chemistry* 45(8): 1672–1677. <https://doi.org/10.1021/jm010997w>
- Martinez VR, Aguirre MV, Todaro JS, Piro OE, Echeverría GA, Ferrer EG, Williams PAM (2018) Azilsartan and its Zn(II) complex. Synthesis, anticancer mechanisms of action and binding to bovine serum albumin. *Toxicology in Vitro* 48: 205–220. <https://doi.org/10.1016/j.tiv.2018.01.009>
- Medvetz DA, Hindi KM, Panzner MJ, Ditto AJ, Yun YH, Youngs WJ (2008) Anticancer Activity of Ag(I) N-Heterocyclic Carbene Complexes Derived from 4,5-Dichloro-1H-Imidazole. *Metal-Based Drugs* 2008: 384010. <https://doi.org/10.1155/2008/384010>
- Mital M, Ziora Z (2018) Biological applications of Ru(II) polypyridyl complexes. *Coordination Chemistry Reviews* 375: 434–458. <https://doi.org/10.1016/j.ccr.2018.02.013>
- Mohammed HS, Tripathi VD (2020) Medicinal Applications of Coordination Complexes. *Journal of Physics: Conference Series* 1664(1): 012070. <https://doi.org/10.1088/1742-6596/1664/1/012070>
- Momekov G, Momekova D, Peykov P, Lambov N (2013) State-of-the-Art Nanopharmaceutical Drug Delivery Platforms for Antineoplastic Agents. *Frontiers in Anti-Cancer Drug Discovery* 2: 282–368. <https://doi.org/10.2174/9781608058082113020011>
- Mora M, Gimeno MC, Visbal R (2019) Recent advances in gold–NHC complexes with biological properties. *Chemical Society Reviews* 48(2): 447–462. <https://doi.org/10.1039/C8CS00570B>
- Niroomand S, Jahanara A, Jahani S, Sargazi G, Patrick BO, Noroozfar M, Khorasani-Motlagh M (2023) A novel binuclear Lanthanum complex containing 1, 10-phenanthroline; from crystal structure to biological and antitumor activity. *Journal of Photochemistry and Photobiology A: Chemistry* 441(11): 114711. <https://doi.org/10.1016/j.jphotochem.2023.114711>
- Nunes DM, Pessatto LR, Mungo D, Oliveira RJ, de Campos Pinto LM, da Costa Iemma MR, Duarte AP (2020) New complexes of usnate with lanthanides ions: La (III), Nd (III), Tb (III), Gd (III), synthesis, characterization, and investigation of cytotoxic properties in MCF-7 cells. *Inorganica Chimica Acta* 506: 119546. <https://doi.org/10.1016/j.ica.2020.119546>
- Pearson RG (1963) Hard and soft acids and bases. *Journal of the American Chemical Society* 85(22): 3533–3539. <https://doi.org/10.1021/ja00905a001>
- Pearson RG (2005) Chemical hardness and density functional theory. *Journal of Chemical Sciences* 117(5): 369–377. <https://doi.org/10.1007/BF02708340>
- Poynton FE, Bright SA, Blasco S, Williams DC, Kelly JM, Gunnlaugsson T (2017) The development of ruthenium(ii) polypyridyl complexes and conjugates for *in vitro* cellular and *in vivo* applications. *Chemical Society Reviews* 46(24): 7706–7756. <https://doi.org/10.1039/C7CS00680B>
- Qi Y-Y, Liu Y-X, Gan Q, Xiong Y-H, Mao Z-W, Le X-Y (2018) Three new mixed-ligand copper(II) complexes containing glycyl-L-valine and N,N-aromatic heterocyclic compounds: Synthesis, characterization DNA interaction, cytotoxicity and antimicrobial activity. *Applied Organometallic Chemistry* 32(3): e4126. <https://doi.org/10.1002/aoc.4126>
- Ray S, Asthana J, Tanski JM, Shaikh MM, Panda D, Ghosh P (2009) Design of nickel chelates of tetradentate N-heterocyclic carbenes with subdued cytotoxicity. *Journal of Organometallic Chemistry* 694(15): 2328–2335. <https://doi.org/10.1016/j.jorganchem.2009.03.036>
- Reed KC, Bygrave FL (1974) The inhibition of mitochondrial calcium transport by lanthanides and Ruthenium Red. *Biochemical Journal*, 140(2): 143–155. <https://doi.org/10.1042/bj1400143>

- Roat-Malone RM (2007) *Bioinorganic Chemistry: A Short Course*. John Wiley & Sons. [Print ISBN:9780471761136 |Online ISBN:9780470191712] <https://doi.org/10.1002/9780470191712>
- Safinejad M, Rigi A, Zeraati M, Heidary Z, Jahani S, Chauhan NPS, Sargazi G (2022) Lanthanum-based metal organic framework (La-MOF) use of 3,4-dihydroxycinnamic acid as drug delivery system linkers in human breast cancer therapy. *BMC Chemistry* 16(1): 93. <https://doi.org/10.1186/s13065-022-00886-y>
- Sagarik KP, Rode BM (1983) Quantum chemical investigations on group IA and IIA metal ion DNA base complexes. *Inorganica Chimica Acta* 76(C): L209–L212. [https://doi.org/10.1016/S0020-1693\(00\)81510-8](https://doi.org/10.1016/S0020-1693(00)81510-8)
- Sarkar AR, Ghosh P (1983) Interaction of divalent metal ions with uracil. I. Oxygen coordinating uracil complexes of Mn(II), Fe(II), Co(II), Ni(II) and Cu(II). *Inorganica Chimica Acta* 78(C): L39–L41. [https://doi.org/10.1016/S0020-1693\(00\)86471-3](https://doi.org/10.1016/S0020-1693(00)86471-3)
- Selvaganapathy M, Raman N (2016) Pharmacological Activity of a Few Transition Metal Complexes: A Short Review. *Journal of Chemical Biology & Therapeutics* 1(2): 108. <https://doi.org/10.4172/2572-0406.1000108>
- Singh UP, Singh BN, Ghose AK, Singh RK, Sodhi A (1991) Synthesis, characterization, and antitumor activity of 5-iodouracil complexes. *Journal of Inorganic Biochemistry* 44(4): 277–282. [https://doi.org/10.1016/0162-0134\(91\)84033-6](https://doi.org/10.1016/0162-0134(91)84033-6)
- Song WJ, Cheng JP, Jiang DH, Guo L, Cai MF, Yang HBin, Lin QY (2014) Synthesis, interaction with DNA and antiproliferative activities of two novel Cu(II) complexes with Schiff base of benzimidazole. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 121: 70–76. <https://doi.org/10.1016/j.saa.2013.09.142>
- Song X-Q, Wang Z-G, Wang Y, Huang Y-Y, Sun Y-X, Ouyang Y, Xie C-Z, Xu J-Y (2020) Syntheses, characterization DNA/HSA binding ability and antitumor activities of a family of isostructural binuclear lanthanide complexes containing hydrazine schiff base. *Journal of Biomolecular Structure and Dynamics* 38(3): 733–743. <https://doi.org/10.1080/07391102.2019.1587511>
- Stanojkovic TP, Kovala-Demertzi D, Primikyri A, Garcia-Santos I, Castineiras A, Juranic Z, Demertzis MA (2010) Zinc(II) complexes of 2-acetyl pyridine 1-(4-fluorophenyl)-piperazinyl thiosemicarbazone: Synthesis, spectroscopic study and crystal structures – Potential anticancer drugs. *Journal of Inorganic Biochemistry* 104(4): 467–476. <https://doi.org/10.1016/j.jinorgbio.2009.12.021>
- Tan XJ, Liu HZ, Ye CZ, Lou JF, Liu Y, Xing DX, Li SP, Liu SL, Song LZ (2014) Synthesis, characterization and in vitro cytotoxic properties of new silver(I) complexes of two novel Schiff bases derived from thiazole and pyrazine. *Polyhedron* 71: 119–132. <https://doi.org/10.1016/j.poly.2014.01.014>
- Tang B, Wan D, Wang YJ, Yi QY, Guo BH, Liu YJ (2018) An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway. *European Journal of Medicinal Chemistry* 145: 302–314. <https://doi.org/10.1016/j.ejmech.2017.12.087>
- Turel I (2015) Special issue: Practical Applications of metal complexes. *Molecules* 20(5): 7951–7956. <https://doi.org/10.3390/molecules20057951>
- Wang B-d, Yang Z-Y, Crewdson P, Wang D-q (2007) Synthesis, crystal structure and DNA-binding studies of the Ln(III) complex with 6-hydroxychromone-3-carbaldehyde benzoyl hydrazone. *Journal of Inorganic Biochemistry* 101(10): 1492–1504. <https://doi.org/10.1016/j.jinorgbio.2007.04.007>
- Wang Q, Yang ZY, Qi GF, Qin DD (2009) Synthesis, crystal structure, antioxidant activities and DNA-binding studies of the Ln(III) complexes with 7-methoxychromone-3-carbaldehyde-(4'-hydroxy) benzoyl hydrazone. *European Journal of Medicinal Chemistry* 44(6): 2425–2433. <https://doi.org/10.1016/j.ejmech.2008.10.023>
- Wason MS, Zhao J (2013) Cerium oxide nanoparticles: potential applications for cancer and other diseases. *American Journal of Translational Research* 5(2): 126. [pmc/articles/PMC3612509/]
- Weng Y, Shen J, Xia Y, Shi Y (2018) Synthesis and Crystal Structure of Two New Zn(II) and Ni(II) Complexes with Anti-Gastric Cancer Activity. *Latin American Journal of Pharmacy (Formerly Acta Farmacéutica Bonaerense)* 37(1): 113–120.
- Xu ZH, Xi PX, Chen FJ, Zeng ZZ (2009) Synthesis, characterization, and DNA-binding of Ln(III) complexes with 2-hydroxybenzylidene-2-phenylquinoline-4-carbonylhydrazone. *Journal of Coordination Chemistry* 62(13): 2193–2202. <https://doi.org/10.1080/00958970902773833>
- Yang Z, Rodgers MT (2005) Influence of methylation on the properties of uracil and its noncovalent interactions with alkali metal ions: Threshold collision-induced dissociation and theoretical studies. *International Journal of Mass Spectrometry* 241(2–3): 225–242. <https://doi.org/10.1016/j.ijms.2004.11.018>
- Yi QY, Wan D, Tang B, Wang YJ, Zhang WY, Du F, He M, Liu YJ (2018) Synthesis, characterization and anticancer activity in vitro and in vivo evaluation of an iridium (III) polypyridyl complex. *European Journal of Medicinal Chemistry* 145: 338–349. <https://doi.org/10.1016/j.ejmech.2017.11.091>
- Zhang HR, Meng T, Liu YC, Chen ZF, Liu YN, Liang H (2016) Synthesis, characterization and biological evaluation of a cobalt(II) complex with 5-chloro-8-hydroxyquinoline as anticancer agent. *Applied Organometallic Chemistry* 30(9): 740–747. <https://doi.org/10.1002/aoc.3498>
- Zhang P, Sadler PJ (2017) Redox-active metal complexes for anticancer therapy. *European Journal of Inorganic Chemistry* 2017(12): 1541–1548. <https://doi.org/10.1002/ejic.201600908>
- Zheng H-L, Zhao Z-Q, Zhang C-G, Feng J-Z, Ke Z-L, Su M-J (2000) Changes in lipid peroxidation, the redox system and ATPase activities in plasma membranes of rice seedling roots caused by lanthanum chloride. *BioMetals* 13: 157–163. <https://doi.org/10.1023/A:1009232821175>
- Zidan AS, Mosbah HK, Aly AA, Ibrahim AB, Mayer P, Saber SH (2022) Synthesis X-ray structure and anticancer activity evaluation of a binuclear La (III) complex with anthranilic acid. *Natural Product Research* 21: 1–10. <https://doi.org/10.1080/14786419.2022.2148246>